Axicabtagene Ciloleucel

Older adults with relapsed/refractory large B-cell lymphoma treated with CD19-directed CAR T-cell therapy have similar survival outcomes to younger patients.

Most serious warning would alert patients, providers on potential risk for secondary malignancies

Our panel discusses findings from the ZUMA-12 study and the ZUMA-7 study

Applies to all approved therapies, but benefits still outweigh risks, agency says

The CAR T-cell therapy led to significantly longer overall survival

A look back at some of the top stories in 2022

Post-treatment cases grow to 22 since products' initial approvals

Patient preference, ease of administration, AEs may all weigh into treatment decisions

Could one of your patients benefit from clinical trials now looking for patients with leukemia or lymphoma?

New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

Systematic review and meta-analysis finds CAR T-cell-specific toxicities only account for 11.5%

Durable response possible with treatment targeting a different antigen

Study results show impressive efficacy, favorable safety profile in the second line

Infections, cardiopulmonary disease, and second cancers were among the leading causes of nonrelapse deaths in patients receiving CAR T-cell therapy, both in clinical trials and clinical practice.

Could one of your patients benefit from the latest clinical trials enrolling patients with leukemia or lymphoma?

An analysis of the FAERS database found the incidence of secondary cancers following CAR T therapy represented 4.3% of all adverse events; however, only 0.1% were secondary T-cell malignancies.

The FDA has determined that the risk for lymphoma and other T-cell cancers may apply to approved BCMA- and CD-19–directed CAR T-cell immunotherapies.

Ian Flinn, MD, PhD, leads a discussion on ZUMA-7 and the upcoming ZUMA-23 with the study authors

CAR T-cell therapy drug axicabtagene ciloleucel significantly improved overall survival compared with standard second-line treatments in patients with early relapsed or refractory large B-cell lymphoma.

The award-winning actress opened up about her latest health news